Factors Impacting Overall and Event Free Survival Following Post-CAR T-cell Consolidative Hematopoietic Stem Cell Transplant.

[1]  J. Kochenderfer,et al.  A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains , 2021, Nature Reviews Clinical Oncology.

[2]  E. Clappier,et al.  Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia , 2021, Leukemia.

[3]  M. Gönen,et al.  Interventions and Outcomes of Adult Patients with B-ALL Progressing After CD19 Chimeric Antigen Receptor T Cell Therapy. , 2021, Blood.

[4]  J. Pidala,et al.  Impact of total body irradiation based myeloablative conditioning regimen in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant: systematic review and meta-analysis. , 2021, Transplantation and cellular therapy.

[5]  S. Steinberg,et al.  Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Loh,et al.  Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. , 2021, JAMA.

[7]  O. Hrusak,et al.  Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. , 2021, JAMA.

[8]  Snehit Prabhu,et al.  Post-Relapse Outcomes Following Tisagenlecleucel: Poor Survival, Despite Current Salvage Therapies: Results from the Pediatric Real World CAR Consortium (PRWCC) , 2021 .

[9]  Linhui Hu,et al.  Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis , 2021, Annals of Hematology.

[10]  G. Wertheim,et al.  Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  B. Burkhardt,et al.  Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Chewning,et al.  A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. , 2020, Blood.

[13]  J. Vose,et al.  Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel. , 2020, Blood.

[14]  Snehit Prabhu,et al.  Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC) , 2020 .

[15]  K. Akashi,et al.  Outcome predictors after retransplantation in relapsed acute lymphoblastic leukemia: a multicenter, retrospective study , 2020, Annals of Hematology.

[16]  S. Steinberg,et al.  Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival , 2020 .

[17]  S. Grupp,et al.  Lingering effects of chemotherapy on mature T cells impair proliferation. , 2020, Blood advances.

[18]  S. Steinberg,et al.  CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Khan,et al.  Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy , 2020, Leukemia.

[20]  Jonathan M. Hernandez,et al.  Intrahepatic cholangiocarcinoma as a rare secondary malignancy after allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia: A case report , 2020, Pediatric transplantation.

[21]  D. Teachey,et al.  Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[22]  Elaine Tan Su Yin,et al.  Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study , 2019, Journal of Hematology & Oncology.

[23]  D. Maloney,et al.  Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes , 2019, Blood.

[24]  M. Sorror,et al.  Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. , 2019, Blood advances.

[25]  E. Jacoby.  The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia , 2019, Bone Marrow Transplantation.

[26]  D. Maloney,et al.  Outcomes of patients with large B‐cell lymphomas and progressive disease following CD19‐specific CAR T‐cell therapy , 2019, American journal of hematology.

[27]  A. Taraseviciute,et al.  What is the Role of Hematopoietic Cell Transplantation (HCT) for Pediatric Acute Lymphoblastic Leukemia (ALL) in the Age of Chimeric Antigen Receptor T-Cell (CART) Therapy? , 2019, Journal of pediatric hematology/oncology.

[28]  T. Fry,et al.  Mechanisms of resistance to CAR T cell therapy , 2019, Nature Reviews Clinical Oncology.

[29]  D. Dimitrov,et al.  Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence , 2019, Clinical Cancer Research.

[30]  D. Barrett.  Improving CAR T cell immunotherapy-mediated remissions for pediatric leukemia. , 2019, The Journal of clinical investigation.

[31]  N. Frey.  Chimeric antigen receptor T cells for acute lymphoblastic leukemia , 2019, American journal of hematology.

[32]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  M. Stetler-Stevenson,et al.  Flow Cytometric Monitoring for Residual Disease in B Lymphoblastic Leukemia Post T Cell Engaging Targeted Therapies , 2018, Current protocols in cytometry.

[34]  I. Yaniv,et al.  Second Hematopoietic Stem Cell Transplantation for Post-Transplantation Relapsed Acute Leukemia in Children: A Retrospective EBMT-PDWP Study. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[35]  C. Keir,et al.  Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia , 2018, Current medical research and opinion.

[36]  Mithat Gonen,et al.  Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[37]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[38]  S. Riddell,et al.  Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. , 2017, Blood.

[39]  D. Porter,et al.  Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[40]  M. Loh,et al.  Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. , 2015, Blood.

[41]  C. Desmarais,et al.  IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. , 2015, Blood.

[42]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[43]  B. Meister,et al.  Outcome of Children and Adolescents With a Second or Third Relapse of Acute Lymphoblastic Leukemia (ALL): A Population-based Analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group , 2013, Journal of pediatric hematology/oncology.

[44]  C. Pui,et al.  Outcomes after induction failure in childhood acute lymphoblastic leukemia. , 2012, The New England journal of medicine.

[45]  P. Gaynon,et al.  Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[46]  K. Kawa,et al.  Second allogeneic hematopoietic SCT for relapsed ALL in children , 2012, Bone Marrow Transplantation.

[47]  M. Loh,et al.  Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  A. Borkhardt,et al.  Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  S. Hunger,et al.  Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.